{
  "symbol": "GILD",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.0833,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.316
  },
  "top_positive": [
    {
      "sent": "2022 Equity Incentive Plan (14) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (15) 10.5* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (16) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (17) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (18) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (19) 10.9* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (20) 10.10* Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) 10.11*, ** Form of global employee s",
      "score": 0.9942
    },
    {
      "sent": "The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 63 $ 75 Short-term marketable debt securities 936 973 Long-term marketable debt securities 1,327 1,245 Total $ 2,326 $ 2,293 13 The following table summarizes our available-for-sale debt securities by contractual maturity: March 31, 2023 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 1,006 $ 999 After one year through five years 1,325 1,308 After five years through ten years 14 14 After ten years 5 5 Total $ 2,350 $ 2,326 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 3,175 $ 3,831 Prepaid and other current assets (1) 394 473 Other long-term assets (1) 982 943 Total $ 4,551 $ 5,248 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments.",
      "score": 0.984
    },
    {
      "sent": "ACQUISITIONS, COLLABO\n one year $ 1,006 $ 999 After one year through five years 1,325 1,308 After five years through ten years 14 14 After ten years 5 5 Total $ 2,350 $ 2,326 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 3,175 $ 3,831 Prepaid and other current assets (1) 394 473 Other long-term assets (1) 982 943 Total $ 4,551 $ 5,248 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments.",
      "score": 0.9801
    }
  ],
  "top_negative": [
    {
      "sent": "DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate March 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50 % $ 750 $ 749 Senior Unsecured September 2020 September 2023 0.75 % 1,499 1,498 Senior Unsecured March 2014 April 2024 3.70 % 1,749 1,748 Senior Unsecured November 2014 February 2025 3.50 % 1,748 1,748 Senior Unsecured September 2015 March 2026 3.65 % 2,742 2,742 Senior Unsecured September 2016 March 2027 2.95 % 1,247 1,247 Senior Unsecured September 2020 October 2027 1.20 % 747 747 Senior Unsecured September 2020 October 2030 1.65 % 994 993 Senior Unsecured September 2015 September\nalid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages.",
      "score": -0.9623
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    }
  ],
  "forward_snippets": [
    "We believe this presentation assists users of the financial statements to better understand cash flow movements.",
    "We do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases.",
    "The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 63 $ 75 Short-term marketable debt securities 936 973 Long-term marketable debt securities 1,327 1,245 Total $ 2,326 $ 2,293 13 The following table summarizes our available-for-sale debt securities by contractual maturity: March 31, 2023 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 1,006 $ 999 After one year through five years 1,325 1,308 After five years through ten years 14 14 After ten years 5 5 Total $ 2,350 $ 2,326 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 3,175 $ 3,831 Prepaid and other current assets (1) 394 473 Other long-term assets (1) 982 943 Total $ 4,551 $ 5,248 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments.",
    "ACQUISITIONS, COLLABO\n one year $ 1,006 $ 999 After one year through five years 1,325 1,308 After five years through ten years 14 14 After ten years 5 5 Total $ 2,350 $ 2,326 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2023 December 31, 2022 Cash and cash equivalents $ 3,175 $ 3,831 Prepaid and other current assets (1) 394 473 Other long-term assets (1) 982 943 Total $ 4,551 $ 5,248 ________________________________ (1) Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments.",
    "Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales."
  ]
}